Literature DB >> 678389

Effects of piretanide, bumetanide and frusemide on electrolyte and urate excretion in normal subjects.

C J Roberts, M Homeida, F Roberts, W Bogie.   

Abstract

1. The pharmacological actions of a new short acting loop diuretic were investigated in nine healthy male subjects and compared with those of frusemide and bumetanide. Subjects received 6 mg piretanide/day, 40 mg frusemide/day or 1 mg bumetanide/day for a period of 1 week. 2. Comparison of effects following the first dose administered showed that 6 mg piretanide is of similar potency to 40 mg frusemide in terms of diuresis, natriuresis and kaliuresis but is less potent than 1 mg bumetanide. 3. All three diuretics caused a decrease in urate excretion and a rise in serum uric acid. 4. Piretanide was well tolerated. Further investigation is required to ascertain what clinical advantage it offers over frusemide and bumetanide.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 678389      PMCID: PMC1429422          DOI: 10.1111/j.1365-2125.1978.tb00837.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  13 in total

1.  Hyperuricemia induced by the administration of chlorthalidone and other sulfonamide diuretics.

Authors:  J M BRYANT; T F YU; L BERGER; N SCHVARTZ; S TOROSDAG; L FLETCHER; M S SCHWARTZ; R B QUAN
Journal:  Am J Med       Date:  1962-09       Impact factor: 4.965

2.  Determinants of response to frusemide in normal subjects.

Authors:  R A Branch; C J Roberts; M Homeida; D Levine
Journal:  Br J Clin Pharmacol       Date:  1977-04       Impact factor: 4.335

3.  Renal action, therapeutic use, and pharmacokinetics of the diuretic bumetanide.

Authors:  D L Davies; A F Lant; N R Millard; A J Smith; J W Ward; G M Wilson
Journal:  Clin Pharmacol Ther       Date:  1974-02       Impact factor: 6.875

4.  Bumetanide, a new potent diuretic. A clinical evaluation in congestive heart failure.

Authors:  K H Olesen; B Sigurd; E Steiness; A Leth
Journal:  Acta Med Scand       Date:  1973 Jan-Feb

5.  Urinary excretion of sodium and potassium in relation to plasma aldosterone concentration.

Authors:  A R Adamson; S W Jamieson
Journal:  J Endocrinol       Date:  1972-06       Impact factor: 4.286

6.  Aldosterone and its regulation during diuresis in patients with gross congestive heart failure.

Authors:  M G Nicholls; E A Espiner; R A Donald; H Hughes
Journal:  Clin Sci Mol Med       Date:  1974-10

Review 7.  Control of uric acid excretion.

Authors:  T H Steele
Journal:  N Engl J Med       Date:  1971-05-27       Impact factor: 91.245

Review 8.  Control of sodium reabsorption.

Authors:  H E de Wardener
Journal:  Br Med J       Date:  1969-09-13

9.  The influence of hypertonic saline infusions upon the fractional reabsorption of urate and other ions in normal and hypertensive man.

Authors:  P J Cannon; D S Svahn; F E Demartini
Journal:  Circulation       Date:  1970-01       Impact factor: 29.690

10.  Furosemide and bumetanide: a study of responses in normal English and German subjects.

Authors:  R A Branch; P R Read; D Levine; E V Elst; J Shelton; W Rupp; L E Ramsay
Journal:  Clin Pharmacol Ther       Date:  1976-05       Impact factor: 6.875

View more
  27 in total

1.  Interaction between salicylate and two loop diuretics.

Authors:  H Valette; E Apoil
Journal:  Br J Clin Pharmacol       Date:  1979-12       Impact factor: 4.335

Review 2.  Diuretics. Clinical pharmacology and therapeutic use (Part I).

Authors:  A Lant
Journal:  Drugs       Date:  1985-01       Impact factor: 9.546

3.  Comparison of the short-term effects of the loop diuretic piretanide and furosemide in patients with renal insufficiency.

Authors:  C Marone; F C Reubi; W Lahn
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

4.  Variance comparison as a tool in clinical pharmacology: an example with two loop diuretics.

Authors:  J L Imbs; M Schmidt; A Spriet; J Schwartz
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

5.  Protein binding of piretanide in normal and uraemic serum.

Authors:  H L Elliott; A F Ansari; B C Campbell; J R Lawrence
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

Review 6.  Piretanide. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy.

Authors:  S P Clissold; R N Brogden
Journal:  Drugs       Date:  1985-06       Impact factor: 9.546

7.  Diuretic activity, safety and pharmacokinetics of torasemide during chronic treatment in normal subjects.

Authors:  Y Ambroes; I Ronflette; L Dodion
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

8.  Study of the tolerance and diuretic properties of torasemide following oral or intravenous administration to healthy volunteers.

Authors:  R Lambe; O Kennedy; M Kenny; A Darragh
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

9.  Oral piretanide in chronic renal failure.

Authors:  I S Henderson; T J Beattie; A C Kennedy; S L Dombey
Journal:  Br J Clin Pharmacol       Date:  1982-12       Impact factor: 4.335

10.  Acute and chronic effects of a diuretic monotherapy with piretanide in congestive heart failure--a placebo-controlled trial.

Authors:  W Haerer; U Bauer; N Sultan; K Cernoch; N Mouselimis; K J Fehske; M Hetzel; M Stauch; V Hombach
Journal:  Cardiovasc Drugs Ther       Date:  1990-04       Impact factor: 3.727

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.